Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era

This retrospective real-world target trial emulation uses complete Czech nationwide registry data to evaluate whether molnupiravir treatment is associated with lower COVID-19 mortality during the Omicron era. The study compares adults with confirmed acute COVID-19 treated with molnupiravir in addition to standard care versus matched controls treated with standard care without molnupiravir. Patients are followed for three months from time zero, and primary endpoints are the COVID-19 case fatality rate and all-cause mortality.

NCT Number	NCT07720596
Lead Sponsor	Charles University, Czech Republic Collaborators: Institute of Health Information and Statistics of the Czech Republic
Conditions	COVID-19, SARS-CoV-2
Enrollment	1,814,551 participants
Start Date	2022-01-01
Primary Completion	2024-12-31 (estimated)
Study Completion	2024-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-22